IPO registrations (S-1, F-1) · Registrants
INTERPACE BIOSCIENCES, INC.
- SEC CIK
- 1054102 · filings on EDGAR ↗
- Former names
- Interpace Diagnostics Group, Inc. (2015–2019); PDI INC (2002–2015); PROFESSIONAL DETAILING INC (1998–2002)
- Registration
- Form S-1, first filed 1998-02-13, last 2026-10-30; 4 initial registrations, 11 amendments
- Outcome
- Final prospectus filed 1998-05-20; declared effective 2011-07-15; withdrawal requested 2022-06-16
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- WATERVIEW PLAZA, SUITE 310, 2001 ROUTE 46, Parsippany, NJ 07054
- EIN
- 22-2919486
- Ticker
- IDXG (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- INTERPACE BIOSCIENCES, INC. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 1998-05-19)
- Final price
- $16.00 per share, within the range (424B1 filed 1998-05-20, an initial public offering)
- Shares sold
- 2,800,000
- Gross proceeds
- $44,800,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol PDII
- Lead underwriters
- Morgan Stanley (706,668 shares)
- Syndicate
- William Blair (706,666); Hambrecht & Quist (706,666); Cowen (40,000); Credit Suisse (80,000); Dominick & Dominick, Incorporated (40,000); A.G. Edwards (80,000); Interstate/Johnson Lane Corporation (40,000); Janney Montgomery Scott (40,000); Edward D. Jones & Co., L.P (40,000); Morgan Keegan (40,000); Pennsylvania Merchant Group LTD (40,000); Piper Sandler (40,000); Redwine & Company, Inc (40,000); Citigroup (80,000); C.E. Unterberg, Towbin (40,000); Vector Securities International, Inc (40,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: INTERPACE BIOSCIENCES EXACT (EIN (EXACT))
- Form D issuer: INTERPACE BIOSCIENCES, INC. EXACT (CIK (EXACT))
- SEC filer: INTERPACE BIOSCIENCES, INC. EXACT (CIK (EXACT))
- Person page: Frank J Ryan Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Jo Ann Saitta Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
- Person page: Richard P Micali Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
- Person page: William J Nasgovitz Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Other))
Filings 25
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 1998-02-13 | S-1 | S-1 (registration) | PROFESSIONAL DETAILING INC | 0000889812-98-000439 ↗ |
| 1998-03-30 | S-1/A | S-1/A (amendment) | PROFESSIONAL DETAILING INC | 0000889812-98-000772 ↗ |
| 1998-04-28 | S-1/A | S-1/A (amendment) | PROFESSIONAL DETAILING INC | 0000889812-98-001059 ↗ |
| 1998-05-15 | S-1/A | S-1/A (amendment) | PROFESSIONAL DETAILING INC | 0000889812-98-001265 ↗ |
| 1998-05-19 | S-1/A | S-1/A (amendment) | PROFESSIONAL DETAILING INC | 0000889812-98-001307 ↗ |
| 1998-05-20 | 424B1 | 424B1 (final prospectus) | PROFESSIONAL DETAILING INC | 0000889812-98-001322 ↗ |
| 2011-07-15 | EFFECT | EFFECT (declared effective) | PDI INC | 9999999995-11-002151 ↗ |
| 2015-10-09 | EFFECT | EFFECT (declared effective) | PDI INC | 9999999995-15-002701 ↗ |
| 2017-05-22 | S-1 | S-1 (registration) | Interpace Diagnostics Group, Inc. | 0001493152-17-005686 ↗ |
| 2017-06-07 | S-1/A | S-1/A (amendment) | Interpace Diagnostics Group, Inc. | 0001493152-17-006276 ↗ |
| 2017-06-13 | S-1/A | S-1/A (amendment) | Interpace Diagnostics Group, Inc. | 0001493152-17-006543 ↗ |
| 2017-06-13 | S-1/A | S-1/A (amendment) | Interpace Diagnostics Group, Inc. | 0001493152-17-006560 ↗ |
| 2017-06-15 | EFFECT | EFFECT (declared effective) | Interpace Diagnostics Group, Inc. | 9999999995-17-001551 ↗ |
| 2017-06-16 | S-1MEF | S-1MEF (added securities) | Interpace Diagnostics Group, Inc. | 0001493152-17-006723 ↗ |
| 2017-06-16 | 424B4 | 424B4 (final prospectus) | Interpace Diagnostics Group, Inc. | 0001493152-17-006768 ↗ |
| 2018-10-19 | EFFECT | EFFECT (declared effective) | Interpace Diagnostics Group, Inc. | 9999999995-18-002672 ↗ |
| 2021-12-06 | S-1 | S-1 (registration) | INTERPACE BIOSCIENCES, INC. | 0001493152-21-030511 ↗ |
| 2022-01-03 | S-1/A | S-1/A (amendment) | INTERPACE BIOSCIENCES, INC. | 0001493152-22-000146 ↗ |
| 2022-01-07 | S-1/A | S-1/A (amendment) | INTERPACE BIOSCIENCES, INC. | 0001493152-22-000718 ↗ |
| 2022-01-12 | EFFECT | EFFECT (declared effective) | INTERPACE BIOSCIENCES, INC. | 9999999995-22-000119 ↗ |
| 2022-01-13 | 424B4 | 424B4 (final prospectus) | INTERPACE BIOSCIENCES, INC. | 0001493152-22-001088 ↗ |
| 2022-06-16 | RW | RW (withdrawal request) | INTERPACE BIOSCIENCES, INC. | 0001493152-22-016962 ↗ |
| 2026-09-25 | S-1 | S-1 (registration) | INTERPACE BIOSCIENCES, INC. | 0001493152-26-044208 ↗ |
| 2026-10-01 | S-1/A | S-1/A (amendment) | INTERPACE BIOSCIENCES, INC. | 0001493152-26-045187 ↗ |
| 2026-10-30 | S-1/A | S-1/A (amendment) | INTERPACE BIOSCIENCES, INC. | 0001493152-26-049456 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 1998-05-19 | S-1/A | registration statement | $14.00–$16.00 | 2,800,000 | - | Nasdaq PDII | 3 | from the submission text; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 3 | document ↗ | |
| 1998-05-20 | 424B1 | final prospectus | $16.00 | 2,800,000 | $44,800,000 | Nasdaq PDII | 17 | from the submission text; price sentence, shares headline, proceeds computed, underwriting table 17, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| JACOBSON BETH | Officer | Former Exec VP & GC | 1 | 2006 | |
| Marquard Michael | Officer | CEO; Chief Executive Officer | 5 | 2006–2008 | |
| Smith Jeffrey Edward | Officer | CEO; CFO; Chief Fin'l Officer/Treasurer; VP of Corporate Development | 18 | 2006–2014 | |
| CURTI JOSEPH I | Director | 4 | 2006–2009 | ||
| FEDERSPIEL JOHN | Director | 12 | 2006–2015 | ||
| PIETRUSKI JOHN M | Director | 5 | 2006–2009 | ||
| RYAN FRANK J | Director | 8 | 2006–2011 | person page Fuzzy | |
| SULLIVAN STEPHEN J | Director | 16 | 2006–2026 | ||
| VECSI JAN MARTENS | Director | 8 | 2006–2010 | ||
| McCarthy Nancy | Officer | EVP, Human Resources | 4 | 2006–2008 | |
| BUDD STEVEN K | Officer | President | 1 | 2006 | |
| COTUGNO STEPHEN | Officer | Executive Vice-President | 1 | 2006 | |
| STOVER JACK E | Director; Director,Officer; Other | Interim President and CEO; President and CEO | 23 | 2006–2020 | |
| Connolly Kevin | Officer | EVP, Marketing Services; Executive vice-president | 4 | 2006–2008 | |
| Belle Gerald P. | Director | 14 | 2008–2015 | ||
| Farrell James G. | Officer | CFO; VP, Corporate Controller | 3 | 2008 | |
| Lurker Nancy | Director,Officer; Officer | CEO | 14 | 2008–2015 | |
| LUBATKIN VERONICA | Director | 6 | 2008–2013 | ||
| Drazner Howard | Officer | President, Pharmakon; SVP,Bus. Dev Medical Education | 4 | 2009–2010 | |
| Tilles Peter | Officer | President, TVG | 1 | 2009 | |
| Micali Richard P | Officer | Senior VP, Sales Services | 5 | 2009–2011 | person page Fuzzy |
| Kerr David E | Officer | Senior VP Business Development | 6 | 2009–2011 | |
| Likoff Robert Owen | Officer | Co-CEO, Group DCA | 1 | 2010 | |
| Davis Jack | Officer | Co-CEO, Group DCA | 1 | 2010 | |
| Melillo Gerald R JR | Officer | President, Sales Services; SVP, Business Development | 9 | 2011–2015 | |
| Saitta Jo Ann | Officer | PDI SVP IT, GM GROUP DCA; SVP and CIO, GM GROUP DCA | 4 | 2012–2013 | person page Fuzzy |
| Climaco John M | Director | 3 | 2013–2014 | ||
| Dreismann Heiner | Director | 3 | 2014–2015 | ||
| Miao Graham G | Officer | CFO | 5 | 2014–2015 | |
| HEARTLAND ADVISORS INC | Other; TenPercentOwner | 2 | 2015–2016 | ||
| NASGOVITZ WILLIAM J | Other; TenPercentOwner | 2 | 2015–2016 | person page Fuzzy | |
| Ratnam Kapila | Director | 1 | 2015 | ||
| Glorikian Harry | Director | 2 | 2016 | ||
| KEEGAN JOSEPH D | Director | 7 | 2016–2026 | ||
| Krishnamurti Nat | Officer | Interim CFO | 2 | 2016 | |
| Early James | Officer; Other | Chief Financial Officer | 10 | 2016–2020 | |
| Richard Gregory | Officer | Chief Commercial Officer; Chief Commerical Officer | 8 | 2017–2020 | |
| Schnoll-Sussman Felice | Director | 3 | 2017–2018 | ||
| Freeburg Thomas John | Officer | Chief Accounting Officer; Chief Financial Officer | 3 | 2018–2021 | |
| Ampersand 2018 Limited Partnership | TenPercentOwner | 6 | 2019–2026 | ||
| Lev Eric B. | Director; Director,TenPercentOwner | 4 | 2019–2020 | ||
| Gorman Robert J. | Director | 4 | 2019–2021 | ||
| McCarthy Laurence | Director | 2 | 2019–2020 | ||
| 1315 Capital II, L.P. | TenPercentOwner | 3 | 2020–2026 | ||
| Chan Edward | Director | 1 | 2020 | ||
| Rocca Fortunato R. | Director | 3 | 2020–2026 | ||
| Knechtel Fred S. | Officer | Chief Financial Officer | 2 | 2020 | |
| Burnell Thomas W. | Director,Officer | CEO, President & Chairman; President and CEO; President & CEO | 4 | 2020–2026 | |
| Kamin Peter | TenPercentOwner | 2 | 2021 | ||
| AGGARWAL VIJAY | Director | 3 | 2022–2026 | ||
| McCarthy Christopher | Officer | CFO & COO; Chief Financial Officer; Principal Financial Officer | 5 | 2023–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-10-16 | INTERPACE BIOSCIENCES, INC. | Other Health Care | $47,000,000 | $47,000,000 | 2 | 1 |
| 2020-01-27 | INTERPACE BIOSCIENCES, INC. | Other Health Care | $47,000,000 | $47,000,000 | 2 | 1 |
| 2019-07-29 | Interpace Diagnostics Group, Inc. | Other Health Care | $27,000,000 | $14,000,000 | 1 | 1 |
| 2017-10-16 | Interpace Diagnostics Group, Inc. | Other Health Care | $5,000,000 | $5,000,000 | 4 | 1 |
| 2017-01-27 | Interpace Diagnostics Group, Inc. | Other Health Care | $4,121,100 | $111,150 | 6 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | INTERPACE BIOSCIENCES | NJ | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | INTERPACE BIOSCIENCES, INC. | NJ | Form D private offerings | CIK (EXACT) |
| SEC filer | INTERPACE BIOSCIENCES, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Interpace Biosciences, Inc. | NJ | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | INTERPACE BIOSCIENCES | EIN (EXACT) | ||
| Person page | Frank J Ryan | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Jo Ann Saitta | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) | |
| Person page | Richard P Micali | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) | |
| Person page | William J Nasgovitz | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Other) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Surgical & Medical Instruments & Apparatus, NJ first:
- ANTARES PHARMA, INC. NJ
- Cytosorbents Corp NJ
- NEPHROS INC NJ
- NUCRYST Pharmaceuticals Corp. NJ
- BAETA CORP NJ
- VALERITAS INC NJ
- Glucotrack, Inc. NJ
- Turnpoint Medical Devices, Inc. NJ
- Valeritas Holdings Inc. NJ
- CHP Merger Corp. NJ
In other datasets, the same topic (Technology) in NJ:
- Form D issuer: A2Zlogix, Inc. (Form D private offerings)
- Lobbying client: 1KOSMOS INC (Federal lobbying (LDA))
Interests: Surgical & Medical Instruments & Apparatus · Technology